Treatment
Dose Escalation clinical trials
We’re tracking 186 recruiting studies that include Dose Escalation, each written for real people, not researchers, below.
Recruiting studies
- NCT05904093RecruitingPhase 1
Check if increasing fostamatinib doses are safe in sickle cell
This Phase 1 study tests whether increasing doses of fostamatinib are safe and tolerated in adults with stable sickle cell disease. It may help researchers understand if the drug could be a future treatment option for people with stable sickle cell.
Bethesda, MarylandAges 18–65 - NCT05987124RecruitingPhase 2
Higher dose defibrotide for SOS after stem cell transplant
This study tests whether a higher dose of defibrotide can help patients who develop SOS/VOD after a stem cell transplant and haven't gotten better with the standard dose. SOS/VOD is a liver condition that sometimes also affects the kidneys or lungs.
Vallhala, New YorkAges 1 month–75 years - NCT06087614RecruitingPhase 2
Higher-dose radiation for head and neck cancer
This trial tests a higher dose of radiation therapy that is adjusted based on oxygen levels in the tumor. It may help people with certain head and neck cancers that have not been treated before.
DelhiAges 18–70 - NCT06177093Recruiting
Higher dose prostate radiation with MRI guidance
This study tests a higher dose of radiation for prostate cancer using an MRI-guided machine (MR-Linac). It aims to see if a more targeted dose can be safely given to the tumor while protecting healthy tissue.
Toronto, OntarioAges 18 years+ - NCT06184035RecruitingPhase 1/Phase 2
Testing a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
Adelaide, South AustraliaAges 18 years+ - NCT06228924RecruitingPhase 1
Gene therapy for ARVC with PKP2 mutation
This trial tests a new gene therapy called TN-401 for people with ARVC caused by a specific PKP2 gene mutation. The goal is to see if the treatment is safe and can help reduce dangerous heart rhythms.
San Francisco, CaliforniaAges 18–65 - NCT06235697RecruitingPhase 3
Hormone therapy with or without lymph node radiation for prostate cancer
This trial tests combining hormone therapy with different types of radiation (including high-dose external beam and brachytherapy) for men with prostate cancer that has a higher chance of coming back. It aims to see if adding radiation to the lymph nodes helps control the cancer better.
Antioch, CaliforniaAges 18 years+ - NCT06293417Recruiting
Study of Ezefeno in patients with high cholesterol and type 2 diabetes
This trial tests a medicine called Ezefeno to see if it helps lower cholesterol in people with type 2 diabetes who are already on statins. It may be an option if you have high triglycerides and other heart risk factors.
SeoulAges 19 years+ - NCT06310967RecruitingPhase 1/Phase 2
Study of IG3018 for high uric acid with or without kidney disease
This trial tests a new medicine, IG3018, to lower high uric acid levels in people with or without chronic kidney disease. It aims to find the right dose and see if it's safe.
Botany, New South WalesAges 18–75 - NCT06328712RecruitingPhase 1/Phase 2
Cell therapy for Charcot-Marie-Tooth type 1A (CMT1A)
This trial tests a new cell therapy called EN001 for people with CMT1A. It aims to see if the treatment is safe and can help with nerve function and muscle weakness.
GyeongjuAges 19 years+ - NCT06330909Recruiting
Focused radiation boost for prostate cancer
This trial tests a newer, more precise radiation treatment that gives a higher dose to the main tumor while keeping radiation to the rest of the prostate the same. It is for men with intermediate- or high-risk prostate cancer who haven't had prior prostate radiation or removal.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT06416007RecruitingPhase 2
Lattice radiation for large tumor palliation
This study tests a new way to deliver radiation called lattice therapy for people with large solid tumors that are causing symptoms. It aims to give a stronger radiation dose to help shrink the tumor and relieve discomfort.
Cincinnati, OhioAges 18 years+ - NCT06446128RecruitingEarly Phase 1
CAR-T cell therapy for B-cell lymphoma that returned or didn't respond
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06476808RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an investigational drug (BMS-986463) in people with advanced solid tumors. It aims to find a safe dose and see if it helps shrink or control the cancer. You must be well enough to do daily activities and have a tumor that can be biopsied before treatment starts.
Los Angeles, CaliforniaAges 18 years+ - NCT06975787RecruitingPhase 1
A New Bispecific Antibody for Lupus Nephritis
This trial is testing a new type of medicine called a 'bispecific antibody' for people whose lupus nephritis has not responded to standard treatments or keeps coming back. The goal is to find a safe dose that might better control the kidney inflammation.
Rochester, MinnesotaAges 18–60 - NCT06592638RecruitingPhase 1
ZG006 for small cell lung cancer
This trial tests a new drug called ZG006 for people with small cell lung cancer that has not responded to or can no longer tolerate standard treatments. The goal is to find the best dose and see if it can help shrink or control the cancer.
Orange, CaliforniaAges 18–75 - NCT06596291RecruitingPhase 1/Phase 2
Gene therapy trial for bladder control after spinal cord injury
This trial tests a new gene therapy called EG110A for people with overactive bladders due to spinal cord injury. It aims to reduce urinary incontinence and may offer an option if other treatments haven't worked well.
Downey, CaliforniaAges 18–75 - NCT06083324Recruiting
Exercise program to improve strength and mobility after cancer
This study tests a personalized exercise program using resistance training (lifting weights) to help cancer survivors rebuild strength, improve body composition, and move better after treatment. It is designed for people who are ready to start exercising safely and want to regain function.
Pittsburgh, PennsylvaniaAges 20–89 - NCT06617169RecruitingPhase 1
Radioactive drug for solid tumors after prior study
This trial tests a new radioactive drug called MNPR-101-PCTA-177Lu for people with solid tumors who already completed a previous study (MNPR-101-D001). It aims to find the safest and most effective dose by carefully monitoring how your body handles the treatment.
North Melbourne, VictoriaAges 18 years+ - NCT06625970RecruitingPhase 3
Darolutamide and high-dose radiation for high-risk prostate cancer
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
BrestAges 18–80 - NCT06636032RecruitingPhase 1/Phase 2
Stem cells for Crohn's fistula treatment
This trial tests whether injecting donated stem cells into complex anal fistulas can help heal them in people with Crohn's disease. You may qualify if you have a fistula that hasn't improved with standard treatments.
ToulouseAges 18 years+ - NCT06651866RecruitingPhase 1
Study of D-CMG for older adults with new AML
This trial tests a new drug combination called D-CMG for people aged 60–75 who have just been diagnosed with a type of leukemia (AML) and cannot have standard chemotherapy. The goal is to find a safe and effective dose.
Xiamen, FujianAges 60–75 - NCT06658535RecruitingPhase 1
Study of NanO2 for mild breathing problems
This trial tests an experimental drug called NanO2 for people with mild respiratory distress who need a small amount of extra oxygen. The goal is to see if it can help improve oxygen levels.
Edmonton, AlbertaAges 18 years+ - NCT06660420RecruitingPhase 1
PRAME-targeted NK cells for advanced melanoma
This trial tests a new type of cell therapy using your own immune cells (NK cells) modified to target a protein called PRAME found on melanoma cells. It is for people whose melanoma has not responded to or has returned after standard immunotherapies.
Houston, TexasAges 18 years+
Common questions
- Are there clinical trials studying Dose Escalation?
- Yes. Clin2 currently lists 186 recruiting studies that include Dose Escalation, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Dose Escalation trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Dose Escalation an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Dose Escalation or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.